Symbols / PCVX Stock $60.81 +0.43% Vaxcyte, Inc.
PCVX (Stock) Chart
About
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 8.83B | Enterprise Value | 7.31B | Income | -766.63M | Sales | — | Book/sh | 20.49 | Cash/sh | 10.85 |
| Dividend Yield | — | Payout | 0.00% | Employees | 507 | IPO | — | P/E | — | Forward P/E | -8.34 |
| PEG | — | P/S | — | P/B | 2.97 | P/C | — | EV/EBITDA | -8.05 | EV/Sales | — |
| Quick Ratio | 7.81 | Current Ratio | 7.91 | Debt/Eq | 4.38 | LT Debt/Eq | — | EPS (ttm) | -5.63 | EPS next Y | -7.29 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-06 | ROA | -17.72% | ROE | -25.59% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 143.92M | Shs Float | 132.23M | Short Float | 10.52% |
| Short Ratio | 10.38 | Short Interest | — | 52W High | 65.00 | 52W Low | 28.09 | Beta | 1.39 | Avg Volume | 1.40M |
| Volume | 746.35K | Target Price | $109.00 | Recom | Strong_buy | Prev Close | $60.55 | Price | $60.81 | Change | 0.43% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-26 | main | BTIG | Buy → Buy | $89 |
| 2026-02-02 | reit | Guggenheim | Buy → Buy | $116 |
| 2025-11-10 | reit | BTIG | Buy → Buy | $85 |
| 2025-10-16 | main | BTIG | Buy → Buy | $85 |
| 2025-09-12 | init | Goldman Sachs | — → Neutral | $38 |
| 2025-04-22 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-04-08 | reit | Needham | Buy → Buy | $90 |
| 2025-04-01 | main | Goldman Sachs | Buy → Buy | $100 |
| 2025-04-01 | main | B of A Securities | Buy → Buy | $137 |
| 2025-04-01 | main | Needham | Buy → Buy | $90 |
| 2025-03-12 | reit | Guggenheim | Buy → Buy | $160 |
| 2025-02-26 | reit | Guggenheim | Buy → Buy | $160 |
| 2025-02-26 | reit | Needham | Buy → Buy | $140 |
| 2025-02-24 | reit | BTIG | Buy → Buy | $160 |
| 2025-02-11 | reit | Needham | Buy → Buy | $14 |
| 2024-12-24 | reit | BTIG | Buy → Buy | $160 |
| 2024-12-20 | init | Goldman Sachs | — → Buy | $135 |
| 2024-11-06 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-11-06 | reit | Needham | Buy → Buy | $140 |
| 2024-09-10 | main | Mizuho | Outperform → Outperform | $163 |
- Trading Systems Reacting to (PCVX) Volatility - Stock Traders Daily Wed, 22 Apr 2026 23
- Vaxcyte management joins Needham virtual healthcare event Apr. 14 - Stock Titan ue, 07 Apr 2026 07
- Vaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial Stage - Insider Monkey hu, 23 Apr 2026 09
- Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. - Yahoo Finance Mon, 02 Mar 2026 08
- Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a 74% Potential Upside in the Innovative Vaccine Sector - DirectorsTalk Interviews Mon, 23 Feb 2026 08
- Is It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump? - Yahoo Finance Fri, 10 Apr 2026 07
- Vaxcyte fills key adult vaccine trial, sets up 2026 Phase 3 data - Stock Titan Mon, 23 Mar 2026 07
- Is It Time To Reassess Vaxcyte (PCVX) After Recent Share Price Recovery - Yahoo Finance Mon, 02 Feb 2026 08
- A 31-strain pneumonia shot showed strong immune responses in adults 50+ - Stock Titan Wed, 18 Mar 2026 07
- Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating - Yahoo Finance Wed, 18 Feb 2026 08
- Vaxcyte (PCVX) COO sells 2,250 shares in planned Rule 10b5-1 trades - Stock Titan Fri, 03 Apr 2026 07
- What Makes Vaxcyte (PCVX) So Attractive - Yahoo Finance Mon, 22 Dec 2025 08
- Elvia Cowan registers 3,000-share sale (PCVX) after option exercise - Stock Titan ue, 07 Apr 2026 07
- Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials - Yahoo Finance hu, 19 Feb 2026 08
- Vaxcyte (PCVX) finance chief sells 3,000 shares after option exercise - Stock Titan Wed, 08 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
923.67
+62.18%
|
569.55
+44.91%
|
393.04
+87.82%
|
209.26
|
| Research And Development |
|
794.31
+66.65%
|
476.64
+43.42%
|
332.34
+96.13%
|
169.45
|
| Selling General And Administration |
|
129.37
+39.25%
|
92.90
+53.05%
|
60.70
+52.47%
|
39.81
|
| General And Administrative Expense |
|
129.37
+39.25%
|
92.90
+53.05%
|
60.70
+52.47%
|
39.81
|
| Other Gand A |
|
129.37
+39.25%
|
92.90
+53.05%
|
60.70
+52.47%
|
39.81
|
| Other Operating Expenses |
|
—
|
—
|
-4.76
-146.76%
|
-1.93
|
| Total Expenses |
|
923.67
+62.18%
|
569.55
+44.91%
|
393.04
+87.82%
|
209.26
|
| Operating Income |
|
-923.67
-62.18%
|
-569.55
-44.91%
|
-393.04
-87.82%
|
-209.26
|
| Total Operating Income As Reported |
|
-923.67
-62.18%
|
-569.55
-21.69%
|
-468.04
-101.52%
|
-232.26
|
| EBITDA |
|
-898.82
-62.33%
|
-553.70
-44.62%
|
-382.87
-78.89%
|
-214.03
|
| Normalized EBITDA |
|
-898.82
-62.33%
|
-553.70
-79.85%
|
-307.87
-61.16%
|
-191.03
|
| Reconciled Depreciation |
|
24.86
+56.89%
|
15.85
+55.79%
|
10.17
+7.60%
|
9.45
|
| EBIT |
|
-923.67
-62.18%
|
-569.55
-44.91%
|
-393.04
-75.87%
|
-223.48
|
| Total Unusual Items |
|
0.00
|
0.00
+100.00%
|
-75.00
-226.16%
|
-23.00
|
| Total Unusual Items Excluding Goodwill |
|
0.00
|
0.00
+100.00%
|
-75.00
-226.16%
|
-23.00
|
| Special Income Charges |
|
0.00
|
0.00
+100.00%
|
-75.00
-226.16%
|
-23.00
|
| Restructuring And Mergern Acquisition |
|
0.00
|
0.00
-100.00%
|
75.00
+226.16%
|
23.00
|
| Net Income |
|
-766.63
-65.25%
|
-463.93
-15.33%
|
-402.27
-80.00%
|
-223.49
|
| Pretax Income |
|
-766.63
-65.25%
|
-463.93
-15.33%
|
-402.27
-80.00%
|
-223.49
|
| Net Non Operating Interest Income Expense |
|
119.72
+8.84%
|
109.99
+74.85%
|
62.91
+653.02%
|
8.35
|
| Interest Expense Non Operating |
|
—
|
0.00
|
0.00
-100.00%
|
0.00
|
| Net Interest Income |
|
119.72
+8.84%
|
109.99
+74.85%
|
62.91
+653.02%
|
8.35
|
| Interest Expense |
|
—
|
0.00
|
0.00
-100.00%
|
0.00
|
| Interest Income Non Operating |
|
119.72
+8.84%
|
109.99
+74.85%
|
62.91
+652.84%
|
8.36
|
| Interest Income |
|
119.72
+8.84%
|
109.99
+74.85%
|
62.91
+652.84%
|
8.36
|
| Other Income Expense |
|
37.33
+953.23%
|
-4.38
+93.93%
|
-72.13
-219.48%
|
-22.58
|
| Other Non Operating Income Expenses |
|
37.33
+953.23%
|
-4.38
-252.55%
|
2.87
+587.77%
|
0.42
|
| Gain On Sale Of Security |
|
—
|
—
|
-1.90
-29.05%
|
-1.47
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-766.63
-65.25%
|
-463.93
-15.33%
|
-402.27
-80.00%
|
-223.49
|
| Net Income From Continuing Operation Net Minority Interest |
|
-766.63
-65.25%
|
-463.93
-15.33%
|
-402.27
-80.00%
|
-223.49
|
| Net Income From Continuing And Discontinued Operation |
|
-766.63
-65.25%
|
-463.93
-15.33%
|
-402.27
-80.00%
|
-223.49
|
| Net Income Continuous Operations |
|
-766.63
-65.25%
|
-463.93
-15.33%
|
-402.27
-80.00%
|
-223.49
|
| Normalized Income |
|
-766.63
-65.25%
|
-463.93
-41.76%
|
-327.27
-63.23%
|
-200.49
|
| Net Income Common Stockholders |
|
-766.63
-65.25%
|
-463.93
-15.33%
|
-402.27
-80.00%
|
-223.49
|
| Diluted EPS |
|
-5.63
-48.16%
|
-3.80
+8.21%
|
-4.14
-20.35%
|
-3.44
|
| Basic EPS |
|
-5.63
-48.16%
|
-3.80
+8.21%
|
-4.14
-20.35%
|
-3.44
|
| Basic Average Shares |
|
136.09
+11.55%
|
122.00
+25.57%
|
97.16
+49.75%
|
64.88
|
| Diluted Average Shares |
|
136.09
+11.55%
|
122.00
+25.57%
|
97.16
+49.75%
|
64.88
|
| Diluted NI Availto Com Stockholders |
|
-766.63
-65.25%
|
-463.93
-15.33%
|
-402.27
-80.00%
|
-223.49
|
| Gain On Sale Of PPE |
|
—
|
—
|
0.00
+100.00%
|
-0.04
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
3,002.72
-14.48%
|
3,511.32
+149.40%
|
1,407.92
+39.93%
|
1,006.18
|
| Current Assets |
|
1,627.36
-8.98%
|
1,787.98
+63.14%
|
1,095.95
+16.27%
|
942.55
|
| Cash Cash Equivalents And Short Term Investments |
|
1,560.96
-10.66%
|
1,747.21
+61.74%
|
1,080.23
+15.98%
|
931.38
|
| Cash And Cash Equivalents |
|
173.96
-55.15%
|
387.88
-2.41%
|
397.45
-52.38%
|
834.66
|
| Cash Equivalents |
|
88.54
-72.95%
|
327.35
-5.79%
|
347.45
-55.37%
|
778.46
|
| Cash Financial |
|
85.42
+41.11%
|
60.53
+21.05%
|
50.00
-11.02%
|
56.20
|
| Other Short Term Investments |
|
1,387.00
+2.04%
|
1,359.33
+99.09%
|
682.78
+605.94%
|
96.72
|
| Prepaid Assets |
|
—
|
—
|
—
|
11.18
|
| Other Current Assets |
|
66.40
+62.84%
|
40.78
+159.28%
|
15.73
+40.68%
|
11.18
|
| Total Non Current Assets |
|
1,375.36
-20.19%
|
1,723.33
+452.42%
|
311.96
+390.33%
|
63.62
|
| Net PPE |
|
491.72
+47.83%
|
332.62
+128.90%
|
145.31
+359.15%
|
31.65
|
| Gross PPE |
|
524.49
+50.33%
|
348.90
+125.70%
|
154.58
+309.33%
|
37.77
|
| Accumulated Depreciation |
|
-32.77
-101.36%
|
-16.27
-75.52%
|
-9.27
-51.58%
|
-6.12
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
338.69
+56.17%
|
216.87
+144.00%
|
88.88
+4291.40%
|
2.02
|
| Construction In Progress |
|
—
|
—
|
—
|
—
|
| Other Properties |
|
178.56
+39.89%
|
127.64
+98.69%
|
64.24
+86.81%
|
34.39
|
| Leases |
|
7.24
+65.12%
|
4.38
+200.27%
|
1.46
+7.91%
|
1.35
|
| Investments And Advances |
|
881.66
-36.46%
|
1,387.51
+752.93%
|
162.68
+512.73%
|
26.55
|
| Non Current Prepaid Assets |
|
—
|
—
|
2.77
-36.53%
|
4.36
|
| Other Non Current Assets |
|
1.97
-38.29%
|
3.20
-19.56%
|
3.98
+273.43%
|
1.06
|
| Total Liabilities Net Minority Interest |
|
317.21
+54.36%
|
205.50
+22.72%
|
167.45
+218.56%
|
52.56
|
| Current Liabilities |
|
205.75
+46.78%
|
140.18
-3.55%
|
145.34
+258.64%
|
40.52
|
| Payables And Accrued Expenses |
|
176.63
+55.30%
|
113.73
-10.56%
|
127.17
+280.35%
|
33.44
|
| Payables |
|
75.61
+55.72%
|
48.55
+232.86%
|
14.59
+48.92%
|
9.79
|
| Accounts Payable |
|
70.90
+46.34%
|
48.45
+232.16%
|
14.59
+48.92%
|
9.79
|
| Current Accrued Expenses |
|
101.02
+54.98%
|
65.18
-42.10%
|
112.58
+376.24%
|
23.64
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
23.00
+11.89%
|
20.55
+85.92%
|
11.06
+836.95%
|
1.18
|
| Total Tax Payable |
|
4.71
+4513.73%
|
0.10
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
6.12
+3.96%
|
5.89
-17.18%
|
7.11
+20.36%
|
5.91
|
| Current Capital Lease Obligation |
|
6.12
+3.96%
|
5.89
-17.18%
|
7.11
+20.36%
|
5.91
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
111.46
+70.63%
|
65.32
+195.41%
|
22.11
+83.65%
|
12.04
|
| Long Term Debt And Capital Lease Obligation |
|
111.36
+70.74%
|
65.22
+194.96%
|
22.11
+83.78%
|
12.03
|
| Long Term Capital Lease Obligation |
|
111.36
+70.74%
|
65.22
+194.96%
|
22.11
+83.78%
|
12.03
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Other Non Current Liabilities |
|
0.10
+0.00%
|
0.10
|
—
|
0.01
|
| Stockholders Equity |
|
2,685.51
-18.76%
|
3,305.82
+166.50%
|
1,240.47
+30.08%
|
953.61
|
| Common Stock Equity |
|
2,685.51
-18.76%
|
3,305.82
+166.50%
|
1,240.47
+30.08%
|
953.61
|
| Capital Stock |
|
0.13
+4.69%
|
0.13
+30.61%
|
0.10
+19.51%
|
0.08
|
| Common Stock |
|
0.13
+4.69%
|
0.13
+30.61%
|
0.10
+19.51%
|
0.08
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
131.06
+4.94%
|
124.89
+30.96%
|
95.36
+20.00%
|
79.47
|
| Ordinary Shares Number |
|
131.06
+4.94%
|
124.89
+30.96%
|
95.36
+20.00%
|
79.47
|
| Additional Paid In Capital |
|
4,838.74
+3.00%
|
4,697.88
+117.03%
|
2,164.58
+46.65%
|
1,476.02
|
| Retained Earnings |
|
-2,154.95
-55.22%
|
-1,388.32
-50.19%
|
-924.39
-77.04%
|
-522.13
|
| Gains Losses Not Affecting Retained Earnings |
|
1.59
+140.98%
|
-3.87
-2263.69%
|
0.18
+149.58%
|
-0.36
|
| Other Equity Adjustments |
|
1.59
+140.98%
|
-3.87
-2263.69%
|
0.18
+149.58%
|
-0.36
|
| Total Equity Gross Minority Interest |
|
2,685.51
-18.76%
|
3,305.82
+166.50%
|
1,240.47
+30.08%
|
953.61
|
| Total Capitalization |
|
2,685.51
-18.76%
|
3,305.82
+166.50%
|
1,240.47
+30.08%
|
953.61
|
| Working Capital |
|
1,421.61
-13.73%
|
1,647.81
+73.34%
|
950.62
+5.39%
|
902.03
|
| Invested Capital |
|
2,685.51
-18.76%
|
3,305.82
+166.50%
|
1,240.47
+30.08%
|
953.61
|
| Total Debt |
|
117.48
+65.21%
|
71.11
+143.33%
|
29.22
+62.89%
|
17.94
|
| Capital Lease Obligations |
|
117.48
+65.21%
|
71.11
+143.33%
|
29.22
+62.89%
|
17.94
|
| Net Tangible Assets |
|
2,685.51
-18.76%
|
3,305.82
+166.50%
|
1,240.47
+30.08%
|
953.61
|
| Tangible Book Value |
|
2,685.51
-18.76%
|
3,305.82
+166.50%
|
1,240.47
+30.08%
|
953.61
|
| Available For Sale Securities |
|
881.66
-36.46%
|
1,387.51
+752.93%
|
162.68
|
—
|
| Investmentin Financial Assets |
|
881.66
-36.46%
|
1,387.51
+752.93%
|
162.68
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-655.58
-44.84%
|
-452.63
-52.51%
|
-296.79
-73.97%
|
-170.60
|
| Cash Flow From Continuing Operating Activities |
|
-655.58
-44.84%
|
-452.63
-52.51%
|
-296.79
-73.97%
|
-170.60
|
| Net Income From Continuing Operations |
|
-766.63
-65.25%
|
-463.93
-15.33%
|
-402.27
-80.00%
|
-223.49
|
| Depreciation Amortization Depletion |
|
24.86
+56.89%
|
15.85
+55.79%
|
10.17
+7.60%
|
9.45
|
| Depreciation |
|
24.86
+56.89%
|
15.85
+55.79%
|
10.17
+7.60%
|
9.45
|
| Depreciation And Amortization |
|
24.86
+56.89%
|
15.85
+55.79%
|
10.17
+7.60%
|
9.45
|
| Other Non Cash Items |
|
-14.43
+62.71%
|
-38.70
-11.30%
|
-34.77
-593.40%
|
7.05
|
| Stock Based Compensation |
|
138.84
+63.69%
|
84.82
+73.96%
|
48.76
+106.17%
|
23.65
|
| Asset Impairment Charge |
|
—
|
—
|
0.00
-100.00%
|
0.21
|
| Operating Gains Losses |
|
-34.77
-921.55%
|
4.23
|
—
|
0.04
|
| Net Foreign Currency Exchange Gain Loss |
|
-34.77
-921.55%
|
4.23
|
0.00
|
0.00
|
| Change In Working Capital |
|
-3.45
+93.71%
|
-54.90
-167.50%
|
81.32
+538.45%
|
12.74
|
| Change In Prepaid Assets |
|
-16.80
-188.31%
|
-5.83
-132.61%
|
17.87
+4027.02%
|
0.43
|
| Change In Payables And Accrued Expense |
|
56.93
+337.10%
|
-24.01
-126.09%
|
92.02
+562.36%
|
13.89
|
| Change In Accrued Expense |
|
37.03
+163.19%
|
-58.60
-172.52%
|
80.80
+634.71%
|
11.00
|
| Change In Payable |
|
19.91
-42.44%
|
34.58
+208.10%
|
11.22
+287.60%
|
2.90
|
| Change In Account Payable |
|
19.91
-42.44%
|
34.58
+208.10%
|
11.22
+287.60%
|
2.90
|
| Change In Other Working Capital |
|
2.30
-75.81%
|
9.52
-3.64%
|
9.88
+534.11%
|
-2.27
|
| Change In Other Current Assets |
|
-92.26
-20.66%
|
-76.46
-53.75%
|
-49.73
-10594.84%
|
-0.47
|
| Change In Other Current Liabilities |
|
46.37
+10.71%
|
41.89
+271.20%
|
11.28
+880.36%
|
1.15
|
| Investing Cash Flow |
|
437.35
+121.81%
|
-2,005.67
-159.36%
|
-773.31
-1136.82%
|
74.58
|
| Cash Flow From Continuing Investing Activities |
|
437.35
+121.81%
|
-2,005.67
-159.36%
|
-773.31
-1136.82%
|
74.58
|
| Net PPE Purchase And Sale |
|
-56.97
+52.19%
|
-119.16
-75.55%
|
-67.88
-1062.08%
|
-5.84
|
| Purchase Of PPE |
|
-56.97
+52.19%
|
-119.16
-75.55%
|
-67.88
-1062.08%
|
-5.84
|
| Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Capital Expenditure |
|
-56.97
+52.19%
|
-119.16
-75.55%
|
-67.88
-1062.08%
|
-5.84
|
| Net Investment Purchase And Sale |
|
494.33
+126.20%
|
-1,886.51
-167.43%
|
-705.43
-977.12%
|
80.43
|
| Purchase Of Investment |
|
-1,211.50
+60.75%
|
-3,086.70
-132.10%
|
-1,329.90
-1194.37%
|
-102.75
|
| Sale Of Investment |
|
1,705.83
+42.13%
|
1,200.19
+92.20%
|
624.46
+240.92%
|
183.17
|
| Financing Cash Flow |
|
2.01
-99.92%
|
2,448.51
+282.69%
|
639.81
-25.74%
|
861.55
|
| Cash Flow From Continuing Financing Activities |
|
2.01
-99.92%
|
2,448.51
+282.69%
|
639.81
-25.74%
|
861.55
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
2,435.66
+282.94%
|
636.04
-25.74%
|
856.48
|
| Proceeds From Stock Option Exercised |
|
13.01
-52.09%
|
27.14
+255.01%
|
7.65
+28.98%
|
5.93
|
| Net Other Financing Charges |
|
-10.99
+23.10%
|
-14.29
-268.73%
|
-3.88
-350.17%
|
-0.86
|
| Changes In Cash |
|
-216.21
-2109.60%
|
-9.79
+97.73%
|
-430.29
-156.21%
|
765.53
|
| Effect Of Exchange Rate Changes |
|
2.44
+472.54%
|
0.43
+106.37%
|
-6.69
-4980.29%
|
0.14
|
| Beginning Cash Position |
|
389.19
-2.35%
|
398.55
-52.30%
|
835.53
+1096.07%
|
69.86
|
| End Cash Position |
|
175.43
-54.93%
|
389.19
-2.35%
|
398.55
-52.30%
|
835.53
|
| Free Cash Flow |
|
-712.55
-24.62%
|
-571.79
-56.80%
|
-364.67
-106.68%
|
-176.44
|
| Interest Paid Supplemental Data |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Amortization Of Securities |
|
—
|
—
|
-34.77
-3572.12%
|
-0.95
|
| Common Stock Issuance |
|
0.00
-100.00%
|
2,435.66
+282.94%
|
636.04
-25.74%
|
856.48
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
2,435.66
+282.94%
|
636.04
-25.74%
|
856.48
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-08 View
- 42026-04-03 View
- 42026-03-18 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-02 View
- 42026-03-02 View
- 42026-03-02 View
- 42026-03-02 View
- 42026-03-02 View
- 8-K2026-02-24 View
- 10-K2026-02-24 View
- 8-K2026-02-24 View
- 8-K2026-02-02 View
- 42026-01-16 View
- 42026-01-16 View
- 42026-01-16 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|